Edwards Lifesciences EW Europe — Cost of Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Edwards Lifesciences in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Edwards Lifesciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Edwards Lifesciences's europe — cost of sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Edwards Lifesciences's europe — cost of sales?
- Edwards Lifesciences (EW) reported europe — cost of sales of $93.6M in Q1 2026.
- How has Edwards Lifesciences's europe — cost of sales changed year-over-year?
- Edwards Lifesciences's europe — cost of sales increased by 13.9% year-over-year, from $82.2M to $93.6M.
- What is the long-term trend for Edwards Lifesciences's europe — cost of sales?
- Over 3 years (2022 to 2025), Edwards Lifesciences's europe — cost of sales has grown at a 12.7% compound annual growth rate (CAGR), from $237.9M to $340.1M.
- What does europe — cost of sales mean?
- This metric captures the direct costs associated with manufacturing and delivering medical devices sold within the European segment. It includes raw materials, labor, and overhead directly attributable to the production of heart valves and related technologies for this market. Monitoring this helps evaluate the production efficiency and cost structure of the European business unit.